SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?


To: Steve Lokness who wrote (503)10/21/2010 8:58:51 PM
From: mcbio  Read Replies (2) | Respond to of 566
 
I posted relevant notes over on iHub (https://www.siliconinvestor.com/nfvda/boards/read_msg.aspx?message_id=55725991&txt2find=rigl ) from RIGL's presentation at the BMO Capital Markets conference on 8/5/10. Of particular note is the fact that RIGL's CEO specifically disclosed RIGL's royalty rate due on FosD sales. There's also good discussion on the rest of the pipeline.